Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity

被引:139
作者
Lubetsky, JB
Swope, M
Dealwis, C
Blake, P
Lolis, E [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA
[2] Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA
[3] Bayer Corp, Div Pharmaceut, Dept Chem, W Haven, CT 06516 USA
关键词
D O I
10.1021/bi990306m
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Macrophage migration inhibitory factor (MIF) is an important immunoregulatory molecule with a unique ability to suppress the anti-inflammatory effects of glucocorticoids. Although considered a cytokine, MIF possesses a three-dimensional structure and active site similar to those of 3-oxalocrotonate tautomerase and 5-carboxymethyl-2-hydroxymuconate isomerase. Moreover, a number of catalytic activities have been defined for MIF. To gain insight into the role of catalysis in the biological function of MIF, we have begun to characterize the catalytic activities in more detail. Here we report the crystal structure of MIF complexed with p-hydroxyphenylpyruvate, a substrate for the phenylpyruvate tautomerase activity of MIF. The three binding sites for p-hydroxyphenylpyruvate in the MIF trimer lie at the interface between two subunits. The substrate interacts with Pro-1, Lys-32, and Ile-64 from one subunit and Tyr-95 and Asn-97 from an adjacent subunit. Pro-1 is positioned to function as a catalytic base. There is no functional group that polarizes the alpha-carbonyl of the substrate to weaken the adjacent C-H bond. Mutation of Pro-1 to glycine substantially reduces the catalytic activity. The insertion of an alanine between Pro-1 and Met-2 essentially abolishes activity. Structural studies of these mutants define a source of the reduced activity and provide insight into the mechanism of the catalytic reaction.
引用
收藏
页码:7346 / 7354
页数:9
相关论文
共 46 条
  • [21] CRYSTAL-STRUCTURE OF THE MUTANT YEAST TRIOSEPHOSPHATE ISOMERASE IN WHICH THE CATALYTIC BASE GLUTAMIC-ACID-165 IS CHANGED TO ASPARTIC-ACID
    JOSEPHMCCARTHY, D
    ROST, LE
    KOMIVES, EA
    PETSKO, GA
    [J]. BIOCHEMISTRY, 1994, 33 (10) : 2824 - 2829
  • [22] Specific reduction of insulin disulfides by macrophage migration inhibitory factor (MIF) with glutathione and dihydrolipoamide: potential role in cellular redox processes
    Kleemann, R
    Mischke, R
    Kapurniotu, A
    Brunner, H
    Bernhagen, J
    [J]. FEBS LETTERS, 1998, 430 (03): : 191 - 196
  • [23] Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase
    Kleemann, R
    Kapurniotu, A
    Frank, RW
    Gessner, A
    Mischke, R
    Flieger, O
    Jüttner, S
    Brunner, H
    Bernhagen, J
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1998, 280 (01) : 85 - 102
  • [24] WHERE FREEDOM IS GIVEN, LIBERTIES ARE TAKEN
    KLEYWEGT, GJ
    JONES, TA
    [J]. STRUCTURE, 1995, 3 (06) : 535 - 540
  • [25] The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat
    Lan, HY
    Bacher, M
    Yang, NS
    Mu, W
    NikolicPaterson, DJ
    Metz, C
    Meinhardt, A
    Bucala, R
    Atkins, RC
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (08) : 1455 - 1465
  • [26] Lolis E, 1996, P ASSOC AM PHYSICIAN, V108, P415
  • [27] LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P808
  • [28] Metz CN, 1997, ADV IMMUNOL, V66, P197, DOI 10.1016/S0065-2776(08)60598-2
  • [29] Mikulowska A, 1997, J IMMUNOL, V158, P5514
  • [30] Muhlhahn P, 1996, PROTEIN SCI, V5, P2095